Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $76 to $53.
July 20, 2023 | 10:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' price target has been lowered from $76 to $53 by Wells Fargo, while maintaining an Equal-Weight rating.
The lowering of the price target by Wells Fargo indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Apellis Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100